M&A / Deals Ipsen charts $1.75bn course for Kartos acquisition PharmaphorumIpsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.HematologyRead full story pharminent June 29, 2026 (Last updated: June 30, 2026) Pharmaphorum Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class. Hematology Read full story Post navigation Previous: Lilly’s Jaypirca receives CHMP positive opinion for CLL in EuropeNext: Viridian wins FDA approval for Lumvoa for thyroid eye disease Related Stories M&A / Deals Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease asset pharminent August 12, 2026 M&A / Deals Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront pharminent August 11, 2026 M&A / Deals Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments pharminent August 7, 2026
